Study guide
15.5 Introduction to Modern Pharmacology vis-à-vis Materia Medica
AIAPGET Homoeopathy All India AYUSH PG Entrance Test
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
Current AIAPGET Homoeopathy Exam Facts Eligibility, Application & Counselling Marking Scheme & Test Strategy
2 Organon Foundations & Cardinal Principles
2.1 History of Homoeopathy & Cardinal Principles 2.2 Vital Force, Health & Disease Concepts 2.3 Law of Similars & Single Remedy 2.4 Minimum Dose & Potentisation Philosophy
3 Case Taking, Analysis & Susceptibility
3.1 Case Taking per Organon Aphorisms 3.2 Analysis, Evaluation & Totality of Symptoms 3.3 Susceptibility, Idiosyncrasy & Reaction
4 Chronic Diseases & Miasms
4.1 Acute vs Chronic Diseases 4.2 Psora: Theory & Clinical Manifestations 4.3 Sycosis: Theory & Clinical Manifestations 4.4 Syphilis & Tubercular / Pseudo-psora Miasms
5 Second Prescription, Philosophy, Psychology & Yoga
5.1 Second Prescription & Remedy Reactions 5.2 Kent's Homoeopathic Philosophy 5.3 Stuart Close, Roberts & Allied Philosophy 5.4 Fundamentals of Psychology & Yoga in Homoeopathic Practice
6 Materia Medica Sources & Study Methods
6.1 Sources & Construction of Materia Medica 6.2 Study Methods, Keynotes & Drug Pictures 6.3 Drug Proving Principles & Pathogenesis
7 Mineral Materia Medica Groups
7.1 Calcarea Group Remedies 7.2 Kali & Natrum Group Remedies 7.3 Arsenicum, Phosphorus & Silicea 7.4 Sulphur, Mercurius & Related
8 Plant Materia Medica Polychrests
8.1 Lycopodium, Nux Vomica & Pulsatilla 8.2 Bryonia, Rhus Toxicodendron & Belladonna 8.3 Aconite, Arnica & Chamomilla 8.4 Thuja, Sepia & Ignatia
9 Animal Remedies, Nosodes & Comparative MM
9.1 Animal Kingdom Remedies 9.2 Nosodes & Sarcodes 9.3 Comparative Materia Medica Technique
10 Repertory History & Major Repertories
10.1 History & Construction of Repertories 10.2 Kent's Repertory: Structure & Use 10.3 Boenninghausen & Boger Repertories
11 Repertorisation Methods & Clinical Repertories
11.1 Methods of Repertorisation 11.2 Rubric Selection & Symptom Grading 11.3 Clinical & Modern Repertories
12 Homoeopathic Pharmacy Foundations
12.1 Sources & Collection of Homoeopathic Drugs 12.2 Mother Tinctures, Vehicles & Trituration 12.3 Potentisation Scales, Succussion & Methods
13 Pharmacopoeia, Posology & Pharmacy Law
13.1 Homoeopathic Pharmacopoeia & Standardisation 13.2 Posology & External Applications 13.3 Pharmacy Legislation & Professional Ethics
14 Practice of Medicine — Core Systems
14.1 Cardiovascular Disorders & Therapeutics 14.2 Respiratory Disorders & Therapeutics 14.3 GI Disorders & Therapeutics 14.4 Neurological & Psychiatric Conditions
15 Practice of Medicine — Extended Systems & Modern Pharmacology
15.1 Endocrine & Metabolic Disorders 15.2 Infectious Diseases & Fevers 15.3 Dermatology & Allergic Conditions 15.4 Renal & Haematological Conditions 15.5 Introduction to Modern Pharmacology vis-à-vis Materia Medica
16 Anatomy, Physiology, Pathology & Forensic
16.1 Anatomy High-Yield for AIAPGET 16.2 Physiology & Biochemistry Essentials 16.3 Pathology & Microbiology Essentials 16.4 Forensic Medicine & Toxicology
17 Surgery & Homoeopathic Surgical Therapeutics
17.1 General Surgery Principles 17.2 ENT, Ophthalmology & Dental Surgery 17.3 Surgical Emergencies & Perioperative Care 17.4 Homoeopathic Therapeutics in Surgery
18 Gynaecology, Obstetrics & Neonatology
18.1 Gynaecological Disorders 18.2 Obstetrics & Antenatal Care 18.3 Labour, Puerperium & Neonatology 18.4 Homoeopathic Therapeutics in ObGyn
19 Community Medicine, Research Methods & Final Revision
19.1 Community Medicine & Public Health 19.2 Research Methodology & Biostatistics 19.3 Final Revision & Exam-Day Strategy
15.5 Introduction to Modern Pharmacology vis-à-vis Materia Medica
Key Takeaways Explain This Topic AI
NCH names the subject "Practice of Medicine with Introduction to Modern Pharmacology" and gives modern pharmacology its own third-professional code (HomUG-Mod.Phar)
Pharmacokinetics is what the body does to the drug (ADME); pharmacodynamics is what the drug does to the body (receptors, agonism, dose-response)
Therapeutic index = LD50 ÷ ED50 — a larger index means a wider safety margin, and steady state is reached after roughly four to five half-lives
Type A adverse reactions are augmented, dose-related and predictable; Type B are bizarre, non-dose-related and idiosyncratic
Organon §74 warns that prolonged allopathic drugging produces artificial chronic disease — drug-induced symptoms must be separated from the natural disease before repertorising
Last updated: August 2026
15.5 Introduction to Modern Pharmacology vis-à-vis Materia Medica
Quick Answer: Pharmacokinetics = ADME (what the body does to the drug). Pharmacodynamics = receptor action and dose-response (what the drug does to the body). Therapeutic index = LD50 ÷ ED50. Steady state arrives after 4-5 half-lives . Type A adverse reactions are dose-related and predictable; Type B are idiosyncratic. Organon §74 is the bridge: chronic allopathic drugging creates artificial disease that contaminates the case image.
The NCH regulations do not treat this as optional. Modern pharmacology appears twice — folded into the Practice of Medicine subject title, and again as a third-professional subject taught explicitly vis-à-vis Homoeopathic Materia Medica. The clinical reason is blunt: almost every chronic patient who walks into a homoeopathic OPD is already on conventional medication, and you cannot take an honest case without knowing which symptoms the pharmacy produced.
Pharmacokinetics — ADME
Phase What happens Exam handle
A bsorption Drug moves from the site of administration into plasma Bioavailability = fraction reaching systemic circulation unchanged; IV bioavailability = 100%
D istribution Drug moves from plasma into tissues Volume of distribution ; plasma protein binding (bound fraction is inactive and non-filterable)
M etabolism Chemical alteration, chiefly hepatic First-pass metabolism reduces oral bioavailability; Phase I (oxidation/reduction/hydrolysis, cytochrome P450) then Phase II (conjugation)
- E xcretion Removal, chiefly renal Renal impairment prolongs half-life of renally cleared drugs
- Half-life arithmetic worth memorising
Half-life (t½) is the time for plasma concentration to fall by half. On regular dosing, plasma level plateaus at steady state after approximately 4-5 half-lives — and, symmetrically, roughly 4-5 half-lives are needed for near-complete washout after stopping. A drug with a 12-hour half-life therefore takes about two to two-and-a-half days to reach steady state, which is why a patient's "new" symptom on day three of a conventional drug may be a pharmacological effect rather than disease progression.
Pharmacodynamics
- Term Definition
- Receptor Macromolecule the drug binds to produce an effect
- Agonist Binds and activates the receptor
- Antagonist Binds with affinity but zero intrinsic activity ; blocks the agonist
- Partial agonist Submaximal response even at full receptor occupancy
- Affinity Tendency to bind the receptor
- Efficacy Maximal effect the drug can produce
- Potency Dose required to produce a given effect
- ED50 Dose effective in 50% of the population
- LD50 Dose lethal in 50% of the test population
- Therapeutic index LD50 ÷ ED50 — larger means safer
Classic distractor: potency and efficacy are swapped constantly. A very potent drug simply works at a smaller dose; it may still have low efficacy. A drug with a narrow therapeutic index (digoxin, lithium, warfarin, phenytoin, aminoglycosides) needs monitoring because the toxic dose sits close to the effective one.
Adverse Drug Reactions
Category Nature Examples of the pattern
Type A (Augmented) Dose-related, predictable from the drug's known pharmacology, common, low mortality Bleeding on an anticoagulant; hypoglycaemia on insulin; bradycardia on a beta-blocker
Type B (Bizarre) Not dose-related, unpredictable, uncommon, higher mortality Anaphylaxis; idiosyncratic hepatotoxicity; severe cutaneous drug reactions
Related vocabulary you should be able to separate cleanly: side effect (unwanted but pharmacologically expected at therapeutic dose), toxic effect (from excessive dose or accumulation), idiosyncrasy (genetically determined abnormal response), allergy (immunologically mediated), teratogenicity (fetal malformation), tolerance (diminishing response on repetition), dependence , and withdrawal/rebound .
Where Modern Pharmacology Meets Materia Medica
Several substances appear in both systems, which is exactly why the Commission asks you to study them side by side.
Substance Modern pharmacology view Homoeopathic view
Digitalis purpurea Cardiac glycoside; positive inotrope, narrow therapeutic index Slow weak irregular pulse, fear the heart will stop on movement
Belladonna / atropine Muscarinic antagonist; mydriasis, dry mouth, flushing, tachycardia Sudden violent congestion, red hot face, throbbing, dilated pupils
Opium Opioid agonist; analgesia, miosis, respiratory depression, constipation Painless torpor, stupor, obstinate constipation without urging
Mercury Heavy-metal toxicant; stomatitis, salivation, nephrotoxicity Offensive salivation, creeping chill, night aggravation, ulceration
The methodological contrast is the actual exam point. Conventional pharmacology characterises a material dose-response relationship in disease , quantified through Phase I-IV clinical trials. Homoeopathic drug proving (Homoeopathic Pathogenetic Trial) records the totality of symptoms produced by the substance in healthy provers, subjective symptoms included, and it is that pathogenetic picture — not the pharmacological mechanism — that authorises the prescription. Same substance; incompatible frameworks; do not answer a proving question with a receptor mechanism.
Organon §74 — Artificial Chronic Disease
Hahnemann attacks prolonged, aggressive allopathic drugging as a producer of artificial chronic diseases superimposed on the natural one. Two practical consequences for case-taking:
Separate the layers. Symptoms that began after a drug was started, are dose-related, and fit that drug's known pharmacology are candidates for drug effect rather than characteristic disease symptoms. Repertorising a beta-blocker's bradycardia as a general is a false totality.
Do not mistake withdrawal for aggravation. A rebound on abrupt cessation is not a homoeopathic aggravation and does not confirm the remedy.
Never stop these abruptly
Corticosteroids, antiepileptics, beta-blockers and other antihypertensives, insulin and oral hypoglycaemics, antithyroid drugs, anticoagulants, and psychotropics all carry real rebound or crisis risk on sudden withdrawal. Tapering is the treating physician's decision and belongs in a co-management conversation — not a unilateral instruction from the homoeopathic side. AIAPGET stems test this as a patient-safety judgement, and the safe answer is always coordinate and taper, never "stop everything so the remedy can act."
- Compact Revision Card
- ADME = absorption, distribution, metabolism, excretion
- Bioavailability IV = 100% ; oral reduced by first-pass metabolism
- Steady state ≈ 4-5 half-lives
- Therapeutic index = LD50 ÷ ED50 ; narrow-index drugs need monitoring
- Potency = dose needed; efficacy = ceiling effect — never interchange
- Type A dose-related and predictable; Type B idiosyncratic and bizarre
- §74 artificial chronic disease from allopathic maltreatment
- Proving is on the healthy ; clinical trials are on the diseased